Clinical Trial Update: To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

A Phase 1 parallel bioavailability study evaluating Leflunomide 20 mg tablets under fasting conditions. The trial, sponsored by Sandoz, is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Leflunomide (Leflunomide)

Snippet

Sponsor: Sandoz | Conditions: Rheumatoid Arthritis, Psoriatic Arthritis | Phase 1 | Status: COMPLETED